Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure

Objective: The utility of topotecan monotherapy for relapsed small-cell lung cancer (SCLC) after failure of amrubicin monotherapy has not been evaluated. We aimed to investigate the efficacy and safety of topotecan monotherapy in patients with relapsed SCLC after amrubicin monotherapy. Patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Nakao, Makoto, Arakawa, Sosuke, Sone, Kazuki, Sato, Hidefumi, Muramatsu, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Association of Rural Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527629/
https://www.ncbi.nlm.nih.gov/pubmed/34707735
http://dx.doi.org/10.2185/jrm.2021-014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527629/
https://www.ncbi.nlm.nih.gov/pubmed/34707735
http://dx.doi.org/10.2185/jrm.2021-014

Ejemplares similares